Close Menu

NEW YORK – The US Food and Drug Administration issued a letter to clinical laboratory staff and healthcare providers Friday, alerting them to the potential for false negative SARS-CoV-2 test results due to mutations in the virus genome.

Through its ongoing analyses of viral sequences and proprietary Emergency Use Authorized test information, the agency has identified three molecular assays whose performance could be impacted by SARS-CoV-2 genetic variants.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.